title: One-year clinical outcomes of the STENTYS Self-Apposing¨ coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry.
abstract: OBJECTIVE
  The aim of APPOSITION III was to evaluate the feasibility and performance of the STENTYS Self-Apposing¨ stent (STENTYS S.A., Paris, France) in the setting of primary percutaneous coronary intervention (PCI).
  
  
  RESULTS
  APPOSITION III was an international, prospective, multicentre registry. The study population consisted of 965 patients. The rate of the primary endpoint major adverse cardiac events (MACE), defined as the composite of cardiac death, recurrent target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularisation (CD-TLR), at one year was 9.3%. One-year cardiac death rate was 2.0%, TV-MI rate was 1.3%, CD-TLR rate was 7.4% and definite/probable stent thrombosis (ST) rate was 3.5% (definite ST 2.8%). An interim safety analysis of in-hospital outcomes in the first 400 patients showed higher event rates if post-dilation was not performed, and post-dilations became highly recommended in the remaining cohort. Patients undergoing post-dilation eventually showed a numerically lower one-year MACE rate (8.4% vs. 11.3%, p=0.137). One-year TV-MI (0.8% vs. 2.5%, p=0.027) and definite ST (1.9% vs. 5.0%, p=0.010) rates were significantly lower if post-dilation was performed, with the divergence occurring at <30 days.
  
  
  CONCLUSIONS
  The use of the STENTYS Self-Apposing¨ stent in the setting of primary PCI was feasible and associated with acceptable cardiovascular event rates which improved when post-dilation was performed.
authors.affiliation: Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
authors.forename: Karel T
authors.initials: KT
authors.lastname: Koch
authors.forename: Maik J
authors.initials: MJ
authors.lastname: Grundeken
authors.forename: Nicola S
authors.initials: NS
authors.lastname: Vos
authors.forename: Alexander J J
authors.initials: AJ
authors.lastname: IJsselmuiden
authors.forename: Robert-Jan
authors.initials: RJ
authors.lastname: van Geuns
authors.forename: Rainer
authors.initials: R
authors.lastname: Wessely
authors.forename: Thomas
authors.initials: T
authors.lastname: Dengler
authors.forename: Alessio
authors.initials: A
authors.lastname: La Manna
authors.forename: Johanne
authors.initials: J
authors.lastname: Silvain
authors.forename: Gilles
authors.initials: G
authors.lastname: Montalescot
authors.forename: René
authors.initials: R
authors.lastname: Spaargaren
authors.forename: Jan G P
authors.initials: JG
authors.lastname: Tijssen
authors.forename: Giovanni
authors.initials: G
authors.lastname: Amoroso
mesh_terms: D002317:Cardiovascular Agents / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood; D008875:Middle Aged; D009203:Myocardial Infarction / Q000175:diagnosis / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000379:methods; D011446:Prospective Studies; D012042:Registries; D015607:Stents; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors